Galderma will present new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting, held in Chicago from November 13-16.
New research shows that loose or sagging skin on the face and neck is most often noted after medication-driven weight loss, with facial changes typically observed 3-6 months following treatment (in 45% of respondents), and sometimes as early as 1-2 months (28%)[1]
In addition, more than 60% of those patients experiencing medication-driven weight
Azzalure also marketed as Dysport outside of the EU for the treatment of glabellar lines marks 10 year anniversary with more than 40 million treatments in the EU and US combined and approval in 72 countries.
Solna, April 23rd 2018 - Today the Nordic affiliates of Janssen and Galderma announced their long-term partnership for the marketing of TREMFYA® (guselkumab) for the treatment of moderate to severe plaque psoriasis.
